TAMIFLU
Added: Apr 03, 2018 3:26 pm Tamiflu- SynopsisSolicitation: SPE2DP-18-R-0110 Agency/Office: DLA Acquisition Locations Location: DLA Troop Support - Medical Title: Oseltamivir Phosphate Classification Code:65-Medical, dental & veterinary equipment & supplies NAICS Code: 325412 - Pharmaceutical Preparation Manufacturing Description(s): The Defense Logistics Agency Troop Support is soliciting proposals for the supply of Oseltamivir Phosphate 75MG Capsules in bottles of 10 each.A requirements contract is proposed with a one-year Base Period. All DoD requirements will be placed on the proposed contract. The estimated quantity for the Base Period is 875,000 bottles.Delivery is to be FOB Destination and delivered within 180 days from date of the delivery order. Contractor is required to deliver to various Contiguous United States (CONUS) locations provided at the time of the delivery order. All responsible sources may submit a proposal and shall be considered by the Agency. The successful contractor shall have FDA approval to sell Oseltamivir Phosphate before award of the contract. Once Solicitation SPE2DP-18-R-0110 is issued, it can be found on the DLA Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil/. The point of contact is Shairy Cartagena, DLA Troop Support-FSAA, 215-737-0730. Place of Performance: Contracting Office Address: 700 Robbins AvenuePhiladelphia, Pennsylvania 19111-5092 United States SPE2DP-18-R-0110 Defense Logistics Agency Troop Support Medical
4/3/18, 3:26 PM Oseltamivir Phosphate
Added: Jan 18, 2018 2:20 pm The Defense Logistics Agency Troop Support is seeking sources capable of providing Oseltamivir Phosphate. DLA Troop Support is contemplating awarding a requirements contract with a one-year base period for Oseltamivir Phosphate 75MG Capsules in bottles of 10 each. The estimated quantity to be ordered is 875,000 bottles. However this quantity may increase or decrease as requirements change.Must have FDA approval to sell Oseltamivir Phosphate before award of the contract.If your firm currently manufactures or distributes Oseltamivir Phosphate, please provide information with respect to the following: a) Place of manufactureb) Estimated annual capacityc) FDA registration d) Product name and description including description of any special featurese) Current unit sale pricef) Estimated inventory level and storage requirementsg) Product shelf life (Months) *** NEW PRODUCTS UNDER DEVELOPMENT***For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture Oseltamivir Phosphate or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support.Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for Oseltamivir Phosphate. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Your response to this FRI may be submitted electronically in pdf format and emailed to cistina.izzi@dla.mil. SPE2DP-18-R-0110 Defense Logistics Agency Troop Support Medical
1/18/18, 2:20 PM